Analytical Tool - Antibodies and Peptides in Oncology


January 7, 2013
SKU: BIOS4940046
License type:
Analytical Tool – Antibodies and Peptides in Oncology offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are four products already appreciated by many of our customers:

Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Cancer Peptides: From First-in-Class to Best-in-Class?

Antibodies in Oncology Drug Pipeline Update 2012*

Peptides in Oncology Drug Pipeline Update 2012*

The Package Includes:
  • A progress analysis on current and emerging drugs
  • Information on most companies active in R&D
  • Information on key industry related projects
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs
This Tool will Assist You in:
  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of antibody and peptide drugs in cancer
  • Identifying emerging products & key areas of pharmaceutical R&D
*This software application is a searchable database reflects the most recent advances in the field of antibody and peptide cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.


Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

More Oncology/Hematology reports by BioSeeker Group AB

Cancer Peptides: From First-in-Class to Best-in-Class? by BioSeeker Group AB
This report gives you a new and unique way of stratifying and analyzing the global peptide pipeline in cancer towards personalized medicine and presents actionable ...
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Peptides by BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound ...
Triple Analysis: Angiogenesis, Antibodies and Peptides by BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Angiogenesis and by the two compound strategies of Antibodies and Peptides. Each ...
Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides by BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy ...
See all reports like this >>